University of Zimbabwe Institutional Repository

Evaluation of the Cavidi Exavir load reverse transcriptase assay (version 3.0) for HIV viral load against the Roche Amplicor Monitor (version 1.5) for use in monitoring viral load in patients infected with the HIV -1 virus.

Show simple item record

dc.contributor.author Gwete, Norah Sukutayi
dc.date.accessioned 2013-06-27T10:01:50Z
dc.date.available 2013-06-27T10:01:50Z
dc.date.issued 2013-06-27
dc.identifier.uri http://hdl.handle.net/10646/1103
dc.description.abstract Title: Evaluation of the Cavidi ExaVir load Reverse Transcriptase Assay (version 3.0) for HIV Viral Load against the Roche Amplicor Monitor (version 1.5) for use in monitoring viral load in patients infected with the HIV virus. Introduction. There are two types of HIV, HIV-1 and HIV-2 and both types are known to cause AIDS, although infection with HIV-1 is more common worldwide. The concentration of HIV RNA in plasma is a critical marker for predicting disease progression and for monitoring the efficacy of antiretroviral drug therapy. However, most viral load assays are not readily available in Zimbabwe due to the complexity and the need for nucleic acid amplification hence the need to explore other available alternatives. The objective of this study was to evaluate the Cavidi ExaVir load Reverse transcription Assay Version 3.0 for quantifying HIV-1 viral load using the Roche Amplicor monitor version 1.5 as the gold standard. Method This was a cross sectional comparative study of two kits where 21 whole blood samples being submitted for viral load testing at Flow cytometry centre were centrifuged and separated within 2 hours of collection and then stored for batched testing with 2 aliquots per sample. The samples were then thawed for testing using the Cavidi Exavir load v 3.0 at flow cytometry centre. The second aliquot was tested using the Roche Amplicor Monitor v1.5 at UZ-UCSF laboratory. The results were then correlated using STATA biostatistics software. Results: There was a very strong linear correlation in viral load measurement between the Cavidi Exavir Load v 3.0 and the Roche Amplicor Monitor v 1.5 ( r=0.94 and p < 0.05). 85.7% of the samples showed an agreement of 0.68 log 10 between the two methods (fivefold) which is equal to the total variation that can be expected in viral load measurements. Conclusion: The Cavidi Exavir load v 3.0 correlates strongly with the Roche Amplicor monitor v 1.5 in measuring plasma viral load concentrations and can be used to monitor viral load in clinical specimens. en_ZW
dc.language.iso en_ZW en_ZW
dc.subject Clinical Epidemiology en_ZW
dc.subject HIV en_ZW
dc.subject Zimbabwe en_ZW
dc.subject Cavidi Exavir en_ZW
dc.subject Roche Amplicor Monitor en_ZW
dc.title Evaluation of the Cavidi Exavir load reverse transcriptase assay (version 3.0) for HIV viral load against the Roche Amplicor Monitor (version 1.5) for use in monitoring viral load in patients infected with the HIV -1 virus. en_ZW
thesis.degree.advisor Gwanzura
thesis.degree.advisor Rusakanaiko, Simbarashe
thesis.degree.country Zimbabwe en_ZW
thesis.degree.discipline Clinical Epidemiology en_ZW
thesis.degree.faculty Faculty of Medicine en_ZW
thesis.degree.grantor University of Zimbabwe en_ZW
thesis.degree.grantoremail specialcol@uzlib.uz.ac.zw
thesis.degree.level MSc en_ZW
thesis.degree.name Master of Science Degree in Clinical Epidemiology en_ZW
thesis.degree.thesistype Thesis en_ZW
dc.date.defense 2012-03


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search UZeScholar


Browse

My Account

xmlui.statisticsGoogleAnalytics.Navigation.title